Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.51 |
| ▸ | MAOB | P27338 | 10/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CTSV | O60911 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11253845 | 0.96 | MAOA (0.52) | MAOAMAOBACHECTSVCTSL | |
| SCHEMBL10342823 | 0.90 | MAOA (0.54) | MAOAMAOBACHEF2CFD | |
| SCHEMBL10343133 | 0.84 | F2 (0.46) | MAOAMAOBACHECTSVCTSL | |
| SCHEMBL10342820 | 0.83 | MAOA (0.57) | MAOAMAOBACHEF2CFD | |
| SCHEMBL175901 | 0.82 | NOS1 (0.53) | CTSVCTSLHTR1AMAPT | |
| SCHEMBL31118759 | 0.80 | MAOA (0.56) | MAOAMAOBACHEF2CFD | |
| SCHEMBL25914584 | 0.80 | MAOA (0.56) | MAOAMAOBACHEF2CFD | |
| SCHEMBL532789 | 0.80 | HTR1A (0.55) | ACHECTSVCTSLHTR1AHTR1D | |
| SCHEMBL5491863 | 0.79 | NOS1 (0.53) | CTSVCTSLMAPT | |
| SCHEMBL12795553 | 0.78 | HTR1A (0.57) | ACHECTSVCTSLHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578757-B1 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2014-10-22 | — | — | EP | disclosed |
| EP-1578757-B1 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2014-10-22 | — | — | EP | disclosed |
| US-7863428-B2 | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2011-01-04 | — | — | US | disclosed |
| US-7863428-B2 | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2011-01-04 | — | — | US | disclosed |
| US-7863428-B2 | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2011-01-04 | — | — | US | disclosed |
| CN-100558738-C | Fluorogenic substrate of enzyme and preparation method thereof | TIBOTEC BVBA (BE) | 2009-11-11 | — | — | CN | disclosed |
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | TIBOTEC BVBA (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | TIBOTEC BVBA (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | TIBOTEC BVBA (BE) | 2007-02-15 | — | — | US | disclosed |
| CN-1732180-A | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2006-02-08 | — | — | CN | disclosed |
| EP-1578757-A2 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | Tibotec BVBA (BE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058787-A2 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | TIBOTEC BVBA (BE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | DNPEP, HEXD, NPEPPS | MAOA 887/4885MAOB 1091/4885ACHE 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.